Journal article
A three-protein biomarker panel assessed in diagnostic tissue predicts death from prostate cancer for men with localized disease
G Severi, LM Fitzgerald, DC Muller, J Pedersen, A Longano, MC Southey, JL Hopper, DR English, GG Giles, J Mills
Cancer Medicine | Published : 2014
DOI: 10.1002/cam4.281
Abstract
Only a minority of prostate cancers lead to death. Because no tissue biomarkers of aggressiveness other than Gleason score are available at diagnosis, many nonlethal cancers are treated aggressively. We evaluated whether a panel of biomarkers, associated with a range of disease outcomes in previous studies, could predict death from prostate cancer for men with localized disease. Using a case-only design, subjects were identified from three Australian epidemiological studies. Men who had died of their disease, "cases" (N = 83), were matched to "referents" (N = 232), those who had not died of prostate cancer, using incidence density sampling. Diagnostic tissue was retrieved to assess expressio..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
Recruitment and follow-up of men participating in the Cancer Council Victoria Prostate Cancer Program was funded by Cancer Council Victoria, VicHealth, Tattersalls, the E. J. Whitten Foundation, and the Prostate Cancer Foundation of Australia. Dr FitzGerald is the Cancer Council Victoria David Hill Fellow and is funded by a Movember and Cure Cancer Australia Foundation Young Investigator Grant awarded through Prostate Cancer Foundation of Australia's Research Program. Further support for this study was provided by the Australian National Health and Medical Research Council (project grant #504700) and by a grant from TissuPath Research Pty Ltd. (a subsidiary of TissuPath Specialist Pathology).